Literature DB >> 22913600

Interleukin-33 in allergy.

Tatsukuni Ohno1, Hideaki Morita, Ken Arae, Kenji Matsumoto, Susumu Nakae.   

Abstract

Interleukin-33 (IL-33) is a member of the IL-1 cytokine family, which includes IL-1 and IL-18, and is considered to be important for host defense against nematodes by inducing Th2 cytokine production via the IL-33 receptor. IL-33 receptor is a heterodimer of IL-1 receptor-like 1 (IL-1RL1; also called ST2, T1, Der4, and fit-1) and IL-1 receptor accessory protein (IL-1RAcP). On the other hand, excessive and/or inappropriate production of IL-33 is considered to be involved in the development of various disorders, such as allergic and autoimmune diseases. Unlike IL-1β and IL-18, IL-33 does not seem to be secreted through the activation of inflammasomes in events such as apoptosis. However, IL-33 is localized in the nucleus of cells and is released during tissue injury associated with necrosis. This suggests that it acts as an alarmin, like IL-1α and high-mobility group box chromosomal protein-1 (HMGB-1). This review summarizes current knowledge regarding the roles of IL-33 in the functions of various cell types and the pathogenesis of allergy.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22913600     DOI: 10.1111/all.12004

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  31 in total

1.  Prolonged activation of IL-5-producing ILC2 causes pulmonary arterial hypertrophy.

Authors:  Masashi Ikutani; Koichi Tsuneyama; Makoto Kawaguchi; Junya Fukuoka; Fujimi Kudo; Susumu Nakae; Makoto Arita; Yoshinori Nagai; Satoshi Takaki; Kiyoshi Takatsu
Journal:  JCI Insight       Date:  2017-04-06

2.  IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs.

Authors:  Chien-Chang Chen; Takao Kobayashi; Koji Iijima; Fan-Chi Hsu; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2017-02-11       Impact factor: 10.793

Review 3.  Emerging role of interleukin-33 in autoimmune diseases.

Authors:  Cheng Pei; Mark Barbour; Karen J Fairlie-Clarke; Debbie Allan; Rong Mu; Hui-Rong Jiang
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

4.  The role of IL-25 and IL-33 in chronic rhinosinusitis with or without nasal polyps.

Authors:  Atakan Ozturan; Hulya Eyigor; Mete Eyigor; Ustun Osma; Mustafa Deniz Yilmaz; Omer Tarik Selcuk; Levent Renda; Meral Gultekin
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-13       Impact factor: 2.503

Review 5.  Rhinovirus and Asthma Exacerbations.

Authors:  Joshua L Kennedy; Sarah Pham; Larry Borish
Journal:  Immunol Allergy Clin North Am       Date:  2019-05-15       Impact factor: 3.479

6.  Possible Role of IL-25 in Eosinophilic Lung Inflammation in Patients with Chronic Eosinophilic Pneumonia.

Authors:  Shigeki Katoh; Masaki Ikeda; Nobuhiro Matsumoto; Hiroki Shimizu; Masaaki Abe; Yoshihiro Ohue; Keiji Mouri; Yoshihiro Kobashi; Masamitsu Nakazato; Mikio Oka
Journal:  Lung       Date:  2017-09-05       Impact factor: 2.584

Review 7.  IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance.

Authors:  Dov B Ballak; Rinke Stienstra; Cees J Tack; Charles A Dinarello; Janna A van Diepen
Journal:  Cytokine       Date:  2015-07-17       Impact factor: 3.861

8.  IL-33/s-ST2 ratio, systemic symptoms, and basophil activation in Pru p 3-sensitized allergic patients.

Authors:  Carina G Uasuf; Caterina Di Sano; Sebastiano Gangemi; Giuseppe Albeggiani; Diego Cigna; Paola Dino; Ignazio Brusca; Mark Gjomarkaj; Elisabetta Pace
Journal:  Inflamm Res       Date:  2018-05-17       Impact factor: 4.575

9.  Interleukin-33 and ST2 Signaling in Tumor Microenvironment.

Authors:  Jaewoo Hong; Soohyun Kim; P Charles Lin
Journal:  J Interferon Cytokine Res       Date:  2018-09-25       Impact factor: 2.607

Review 10.  Type 2 innate lymphocytes in allergic airway inflammation.

Authors:  Roel G J Klein Wolterink; Rudi W Hendriks
Journal:  Curr Allergy Asthma Rep       Date:  2013-06       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.